BioPharma Credit plc (BPCR) ORD USD0.01

Sell:$0.91Buy:$0.92$0.00 (0.43%)

FTSE 250:0.08%
Market closed |
Prices delayed by at least 15 minutes
Sell:$0.91
Buy:$0.92
Change:$0.00 (0.43%)
Market closed |
Prices delayed by at least 15 minutes
Sell:$0.91
Buy:$0.92
Change:$0.00 (0.43%)
Market closed |
Prices delayed by at least 15 minutes

Trust Information

About this company

BioPharma Credit PLC is a United Kingdom-based specialist debt investor to the life sciences industry. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. It seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products. The Company may also invest in equity issued by a life sciences company, acquired directly from the life sciences company or in the secondary market. It will seek to create a diversified portfolio of investments by investing across a range of different forms of debt assets issued by a variety of borrowers. It has two wholly owned subsidiaries: BPCR Limited Partnership and BPCR GP Limited. The Company holds a majority of its investments through its financing subsidiary, BPCR Limited Partnership. Its investment manager is Pharmakon Advisors, LP.

Objective

To generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The Company will seek to achieve its investment objective predominantly through direct or indirect exposure to Debt Assets, which include Royalty Investments, Senior Secured Debt, Unsecured Debt and Credit Linked Notes.

Costs

  • Ongoing charge1.21%
  • Annual management charge1.00% of Net Assets
  • Performance feeYes

Fee structure

Annual management fee is 1% of NAV. The performance fee is calculated as 10% of returns, subject to High Watermark and a 6% preferred return hurdle with 50% catch up.

Value Assessment

  • Value Assessment review date26 March 2025
  • Value Assessment next review date-
  • Is Assessment of Value required under COLL?Yes
  • Outcome of COLL Assessment of ValueCharges are justified based on the results of the assessment, or based on assessment against initial product design if an assessment not yet due
  • Outcome of PRIN Value Assessment or reviewn/a
  • Other review related to value and or charges -
  • Further information-
Click to see more

Key facts

  • Currency
    USD
  • Benchmark
    No benchmark
  • Shares in issue
    1.37bn
  • Gross gearing
    0.00%
  • EPIC
    BPCR
  • ISIN
    GB00BDGKMY29
  • Domicile
    United Kingdom
  • Exchange
    London Stock Exchange (LON)
  • Index
    FTSE All Share Index, Britain-FTSE250-Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview of the company, currency, shares in issue, EPIC, location, exchange, index, website, Data sourced by LSEG. Objective, Costs, Fee Structure, Key facts including Benchmark, Gross gearing are provided by MorningStar.